| INTRODUCTION
Von Willebrand factor (VWF) is a multimeric glycoprotein synthesized by endothelial cells and megakaryocytes/platelets that circulates in the plasma, and plays an essential role in primary hemostasis, mediating the adhesion of platelets to thrombogenic surfaces, and acting as a carrier protein for coagulation factor (F) VIII. 1, 2 In the development of cancer metastasis, tumor cells interact with platelets and the vessel wall to extravasate from the circulation; thus, VWF presents a potential candidate to mediate platelet-tumor cell interactions. 
4,5
The distinctive different molecular sizes of VWF influence its ability to regulate adhesive interactions with platelets. 6 "Unusually large"
VWF multimers (UL-VWFMs) are stored in Weibel-Palade bodies and released into the plasma, where they are rapidly degraded into smaller VWF multimers by the plasma VWF-cleaving protease ADAMTS-13
(a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). ADAMTS-13 specifically cleaves UL-VWFMs between Tyr1605 and Met1606 within the VWF A2 domain. 7 Smaller
VWF multimers, such as VWF-pp, are more rapidly cleared from the circulation than VWF. A deficiency in ADAMTS-13 increases plasma VWF levels, thereby disrupting the balance between levels of VWF and ADAMTS-13, resulting in microcirculatory disturbances. 8, 9 It is known that severe ADAMTS-13 deficiency, due to either mutations in the ADAMTS-13 gene or the presence of inhibitory antibodies, 10,11 is strongly associated with thrombotic thrombocytopenic purpura.
In fact, impaired VWF-cleaving activity of ADAMTS-13 was recently demonstrated in patients with metastasizing and malignant tumors.
Oleksowicz et al. 12 first reported that deficient ADAMTS-13 activity could result in elevated levels of highly polymeric VWF in patients with disseminated malignancies and Koo et al. 13 reported mild ADAMTS-13 deficiency in patients with stage IV colon cancer and various advancedstage malignant tumors. Mannucci et al. 14 also found lower mean levels of ADAMTS-13 activity in patients with disseminated tumors, as compared to those with localized tumors. However, few reports have focused on the contribution of VWF and ADAMTS-13 to the development of advanced non-small-cell lung cancer (NSCLC). Therefore, the purpose of this study was to investigate the balance of VWF secretion and plasma ADAMTS-13 level in patients with advanced NSCLC, and to explore the association of VWF/ADAMTS-13 ratio with the progression or prognosis of advanced NSCLC. 
| MATERIALS AND METHODS

| Patients
| Response to treatment and follow-up
All patients underwent chemotherapy or chemoradiotherapy.
Cisplatin-based chemotherapy included etoposide, irinotecan, gemcitabine, docetaxel, or pemetrexed. The tumor response to chemotherapy was evaluated using computed tomography of the chest and defined according to the revised Response Evaluation Criteria in Solid Tumours (version 1.1). 17 In short, a complete response (CR) was defined as the disappearance of all target lesions; a partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions; progressive disease (PD) was defined as at least a 20%
increase in the sum of diameters of target lesions and that the sum must demonstrate an absolute increase of at least 5 mm; and stable disease (SD) was defined as neither sufficient shrinkage to qualify as a PR nor sufficient increase to qualify as a PD.
The follow-up period for each patient began at the time of blood sampling and ended for overall survival at the occurrence of death, self-withdrawal from the study, or on February 25, 2016, whichever came first. During follow-up, clinical, laboratory, and radiological reassessments were performed at three-to four-week intervals.
Additionally, a telephone interview with the patient or patient's family was established to determine the status of the patients who abandoned the follow-up regimen.
| Sample collection and coagulation assays
Venous blood samples were collected from both the healthy controls and patients in the early morning after overnight fasting into three according to the manufacturer's instructions. The intra-and interassay coefficients of variation for VWF and ADAMTS-13 were <9%
and <11%, respectively, according to the manufacturer.
| Statistical analysis
Continuous variables are expressed as the mean and standard deviation. The mean values of each item between two groups were compared using the Student's ttest and Mann-Whitney U test, whereas differences among the three groups were analyzed using one-way analysis of variance and the Kruskal-Wallis H test, as appropriate for continuous variables. Nonparametric chi-square tests were used to compare categorical variables. Spearman's rank correlation was used to evaluate the relationship between parameters. Univariate analysis of risk factors for their predictive value of patient death was performed using Cox proportional hazard regression analyses. A multivariable stepwise logistic regression test was used to evaluate independent clinical parameters predicting mortality. Receiver-operating characteristic (ROC) curves of the parameters were further obtained, and the differences in the area under the curve (AUC) were tested using the z test. Survival curves were determined using the KaplanMeier method. The log-rank test was used to evaluate differences between survival curves. All statistical analyses were performed using SPSS version 16.0 J for Windows software (IBM-SPSS, Inc., Chicago, IL, USA). A P-value <.05 was considered statistically significant.
| RESULTS
| Comparison of clinical/laboratory parameters between patients and healthy controls
Clinical and laboratory characteristics in advanced NSCLC patients prior to commencing treatment and in healthy controls are shown in Table 1 . Compared to the healthy controls, levels of LDH, D-dimer, fibrinogen, VWF, and F VIII, as well as VWF/ADAMTS-13 ratio were significantly increased, whereas body mass index (BMI) and levels of hemoglobin and ADAMTS-13 were significantly decreased, in the sera or plasma of advanced NSCLC patients. However, there were no significant differences in sex, age, blood group distribution, or smoking status between the two groups.
| Relationship of VWF/ADAMTS-13 ratio with clinical/pathological parameters
The relationships between plasma levels of VWF, ADAMTS-13, F VIII, and VWF/ADAMTS-13 ratio of advanced NSCLC patients and clinical/pathological parameters were analyzed. As shown in Table 2 and there was a significant correlation between chemotherapy response and levels of VWF, VWF/ADAMTS-13 ratio, and F VIII (P=.042, .011, and .049, respectively), but not ADAMTS-13. Besides, plasma levels of VWF, ADAMTS-13, and VWF/ADAMTS-13 ratio were also associated with the final status of disease. Nonsurvivors had higher levels of VWF and VWF/ADAMTS-13 ratio, but lower levels of ADAMTS-13, as compared to survivors (P=.027, .005, and .040, respectively).
The relationship between the VWF/ADAMTS-13 ratio and clinical variables was further analyzed (Table 3) . The VWF/ADAMTS-13 ratio correlated positively with LDH, D-dimer, fibrinogen, VWF, and F VIII and correlated negatively with BMI, hemoglobin, and ADAMTS-13. Figure 2 ). The AUC for the VWF/ADAMTS-13 ratio tended to be highest for the prediction of mortality. However, these differences were not significant among the VWF/ADAMTS-13 ratio, VWF, ADAMTS-13, and D-dimer for prediction of mortality among advanced NSCLC patients.
| Correlation of VWF/ADAMTS-13 ratio with prognosis of NSCLC
The cumulative survival rate of 119 NSCLC patients according to the VWF/ADAMTS-13 ratio is shown in Figure 3 . The median length of survival time was 336 days (95% CI=306-376 days) and 270 days (95% CI=229-310 days), respectively, for patients with low VWF/ADAMTS-13 ratios (≤1.31) and high VWF/ADAMTS-13 ratios (>1.31). As determined by the Kaplan-Meier curves, the probability of survival of patients with a lower VWF/ADAMTS-13 ratio was more favorable than for patients with a higher VWF/ADAMTS-13 ratio (P=.004).
| DISCUSSION
It is well established that clotting activation is frequently encountered in cancer and that the hypercoagulability state is directly involved in cancer progression. 18 Although the biological significance of hemostatic abnormalities in cancer remains unclear, some evidence suggests that the capacity of neoplastic cells to activate the coagulation and fibrinolytic system facilitates their invasive and metastatic behaviors. 19 NSCLC patients are also suspected to be more prone to a hypercoagulable state. In NSCLC, host macrophages release procoagulant factors, which could activate the coagulation and fibrinolytic system. 20 Previous studies showed that prolonged prothrombin time, international normalized ratio, high D-dimer level, and low antithrombin III level were associated with worse survival in lung cancer patients. 21, 22 Additionally, a low ratio of plasmin-α 2 -plasmin inhibitor complex to thrombin-antithrombin complex and low protein S levels were reported as significant independent negative prognostic factors for survival in patients with advanced NSCLC. 23 The plasma VWF level, currently regarded as a marker of endothelial cell activation, is increased in colorectal, breast, and ovarian cancer. It has been suggested that the plasma VWF level may be associated with tumor stage and has prognostic significance in cancer patients. [24] [25] [26] Furthermore, it is known that a deficiency in ADAMTS-13, which is also known as von Willebrand factor-cleaving protease, resulting in the presence of T A B L E 1 Clinical and laboratory characteristics of the study participants UL-VWFM and increased levels of VWF antigen in plasma, was associated with the metastatic process. 13 However, little is known about the association of VWF, ADAMTS-13, and VWF/ADAMTS-13 ratio with histopathological types, pretherapeutic tumor stage and grade, and prognosis in advanced NSCLC.
In the present study, we demonstrated significantly increased levels of VWF and the VWF/ADAMTS-13 ratio, as well as significantly decreased level of ADAMTS-13, in the plasma of advanced NSCLC patients. Furthermore, plasma levels of VWF, ADAMTS-13, and VWF/ ADAMTS-13 ratio were significantly associated with tumor grade, disease stage, and final status of advanced NSCLC patients. Meanwhile, we found increased levels of VWF and VWF/ADAMTS-13 ratio in advanced NSCLC patients with no response to chemotherapy. The results of the present study support the idea that plasma levels of VWF, as well as its cleaving protease ADAMTS-13, possibly play an important role in tumor spread and might be valuable to predict the outcomes of advanced NSCLC patients. These results are in agreement with the findings of Wang et al. 27 and Zietek et al. 28 who reported increased levels of plasma VWF in colorectal and urinary bladder carcinoma and may be correlated with clinical staging and poor prognosis.
Nevertheless, the significant difference found in the present study is inconsistent with the results obtained by Martini et al. 29 who found a similar distribution of VWF between NSCLC patients and control subjects. As the control population consisted of age-and sex-matched healthy subjects in both studies, different prevalence of metastatic disease might explain the discrepancies observed in both studies.
Additionally, the imbalance in the distribution of blood types between patients with NSCLC and healthy controls might explain the lack of T A B L E 2 Results of comparisons between VWF, ADAMTS-13, VWF/ADAMTS-13 ratio, F VIII, and clinical/pathological parameters in patients with advanced NSCLC differences between the two groups in a study by Martini et al. 29 as previous studies demonstrated that the proteolysis of VWF by ADAMTS-13 seems to occur more rapidly in the O blood group, as compared to non-O blood groups, 30,31 thus explaining the higher VWF plasma levels observed in subjects with non-O blood groups. In the present study, we found no significant difference in the distribution of blood groups between advanced NSCLC patients and healthy controls.
The results of the present study also confirmed those of previous studies in that a deficiency in ADAMTS-13 activity was consistently observed in patients with malignancies, especially in advanced or metastatic diseases. 13, 32 However, the severity of ADAMTS-13 deficiency differed among these previous studies, as well as the present study. The different methodology used for measuring plasma ADAMTS-13 levels might account for the variant results among these studies. Another explanation for the variant results may be a consequence of the heterogeneous study population and cancer types. F VIII plays a crucial role in the propagation phase of coagulation activation. The present study also showed higher levels of F VIII activity in patients with a lower BMI, poorly differentiated grade, stage IV, and no response to chemotherapy. In addition, a marginal significant increase in F VIII activity was observed in nonsurvivors, partly in accordance with a previous study which demonstrated that elevated F VIII was associated with an increased risk of thrombosis and a decrease in survival in patients with lung adenocarcinoma. However, despite this association, F VIII activity did not appear to be a significant risk factor for thrombosis and mortality in the multivariate analysis. 33 The effects of disease on F VIII plasma levels may be mainly mediated by VWF, which is well known to carry F VIII and indirectly prevent its plasmatic clearance.
2
The VWF/ADAMTS-13 ratio was reported to be more useful than VWF alone for the diagnosis of hypercoagulability induced by an imbalance between VWF secretion and ADAMTS-13 in patients with organ failure. 34 In the present study, a marked increase in the VWF/ ADAMTS-13 ratio was positively correlated with D-dimer, fibrinogen, and F VIII in advanced NSCLC patients. These results suggest that an imbalance between VWF secretion and ADAMTS-13 level induced by endothelial activation or dysfunction may cause highly prothrombotic states that lead to thrombosis in patients with advanced NSCLC.
Moreover, the results of the present study established for the first time T A B L E 4 Cox regression analyses of risk factors for prediction of patient mortality F I G U R E 2 ROC curves of the VWF/ADAMTS-13 ratio and levels of VWF, ADAMTS-13, and D-dimer for the prediction of mortality in advanced NSCLC F I G U R E 3 Kaplan-Meier analysis survival curves of 119 advanced NSCLC patients according to the VWF/ADAMTS-13 ratio. Differences between groups were evaluated using the log-rank test (P=.004)
especially for UL-VWFMs, 36,37 which could arise due to a deficiency in ADAMTS-13 activity and interactions with more than one ligand at one time. However, it remains unclear whether these tumor-platelet aggregates further augment secretion of VWF from endothelial Weibel-Palade bodies. Nonetheless, we speculate that the reduced ADAMTS-13 activity, which regulates the size and, hence, affects the clearance of VWF from the circulation, might result in an increase in plasma VWF. Although the mechanism that drives the reduction in plasma ADAMTS-13 in cancer patients is not fully understood, various oncogenes have been found to regulate expression of extracellular proteinases, including the matrix-degrading metalloproteinases, which can directly result in perturbations in ADAMTS-13 activity.
38
Additionally, the functional properties of ADAMTS-13 could be impacted by a network of oncogene-mediated kinases via protein phosphorylation, which not only alters the activity of ADAMTS-13
itself, but influence the activities of associated regulatory molecules, cofactors, and docking-type receptors.
12,39
Interestingly, several studies have reported that VWF induces tumor cells to enter apoptosis instead of influencing tumor cell proliferation or invasion. 40, 41 Terraube et al. 4 reported that VWF plays a pro- 42 the mechanism by which VWF inhibits metastasis may be independent of its role in hemostasis. 3 Furthermore, a previous study in mice reported that antibody-mediated inhibition of VWF led to an inhibition of metastasis. 43 Thus, opposite results were found in VWF-null mice compared to an antibody-mediated inhibition study and the present study. Because previous studies indicated that tumorassociated procoagulant activity correlated with increased metastatic potential, 42, 44 the protective role of VWF in metastasis formation is unique. It is noteworthy that mouse experimental metastasis occurs within weeks, whereas human metastases develop over years. 45 Moreover, the extensive intravascular proliferation of metastatic cancer cells in the mouse model differs from the pathogenesis of human metastasis. 46 Further studies are therefore required to confirm and to increase our knowledge of the precise functional mechanism of VWF in tumorigenesis and tumor progression.
There were a few limitations to this study that should be addressed. First, this was a single-center study with a relatively small sample size, which was not large enough to establish the usefulness of the measurement of the preoperative plasma VWF/ADAMTS-13 ratio.
Therefore, the current findings must be confirmed in larger, multicenter, prospective studies. Second, measurement of the VWF antigen was insufficient to arrive at specific information regarding circulating VWF molecular species, such as VWF propeptide and VWF multimers.
A deeper analysis of VWF propeptides, VWF multimers, and VWF activity might be more relevant to reveal the imbalance between VWF secretion and ADAMTS-13 level in cancer patients, and to clarify the mechanisms behind our findings.
| CONCLUSION
In summary, our results demonstrated that an imbalance between VWF secretion and ADAMTS-13 may play a critical role in the hypercoagulability state in patients with advanced NSCLC. A high VWF/ ADAMTS-13 ratio was associated with tumor grade, tumor metastasis, poor response to chemotherapy, and mortality in advanced NSCLC patients. Our study showed that measurement of the plasma VWF/ADAMTS-13 ratio can provide additional data for evaluating the prognosis of advanced NSCLC patients.
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